Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.34 |
| ▸ | GYS1 | P13807 | 2/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487569 | 0.86 | CNR1 (0.36) | — | |
| SCHEMBL17487648 | 0.86 | CNR1 (0.36) | — | |
| SCHEMBL17487665 | 0.83 | S1PR1 (0.32) | — | |
| SCHEMBL16040016 | 0.81 | MAOB (0.55) | MAOBFFAR1MAOAPTGESSENP8 | |
| SCHEMBL19703007 | 0.80 | MAOB (0.59) | MAOBMAOASENP8SENP7SENP6 | |
| SCHEMBL17487658 | 0.78 | S1PR1 (0.33) | — | |
| SCHEMBL17487651 | 0.78 | ALOX5 (0.34) | — | |
| SCHEMBL17487605 | 0.77 | MAOB (0.48) | MAOBFFAR1MAOAPTGESSENP8 | |
| SCHEMBL17487748 | 0.74 | RARB (0.37) | MAOB | |
| SCHEMBL12740516 | 0.74 | FFAR1 (0.43) | MAOBFFAR1MAOAPTGESSENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441161-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9441161-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20160032187-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20160032187-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160032187-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD1, OCIAD2, PIEZO1 | MAOB 1419/4885FFAR1 1307/4885MAOA 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.